Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: J Heart Lung Transplant. 2023 Sep 17;43(1):148–157. doi: 10.1016/j.healun.2023.09.004

Table 2 –

Rejection Outcomes

Total Cohort Propensity-Matched Cohort

DBD DCD p DBD DCD p
n 5582 292 358 152
PRA >10% (%) 869 (21.3) 38 (15.3) 0.031 41 (15.7) 19 (13.1) 0.574
Peak PRA >10% (%) 1127 (27.6) 52 (21.0) 0.027 58 (22.3) 28 (19.3) 0.562
Acute rejection prior to discharge (%) 1027 (18.4) 68 (23.3) 0.044 48 (13.4) 26 (17.1) 0.344
Treated for acute rejection prior to discharge (%) 543 (9.7) 38 (13.0) 0.083 23 (6.4) 17 (11.2) 0.099
Treated for rejection within 1 year (%) 564 (10.1) 38 (13.0) 0.134 22 (6.1) 19 (12.5) 0.025
Hospitalized for rejection (%) 230 (11.4) 18 (23.4) 0.003 9 (8.7) 12 (27.3) 0.007
Follow-up time (months) for hospitalization for rejection (mean (SD)) 14.56 (5.76) 14.98 (6.04) 0.529 14.25 (5.90) 14.91 (5.66) 0.531
Hospitalized for infection (%) 754 (37.5) 33 (42.9) 0.401 44 (42.3) 18 (40.9) 1.000
Follow-up time (months) for hospitalization for infection (mean (SD)) 14.56 (5.76) 14.98 (6.04) 0.522 14.25 (5.90) 14.91 (5.66) 0.531
Coronary vasculopathy (%) 257 (6.8) 11 (6.3) 0.926 11 (5.4) 8 (9.1) 0.365
Follow-up time (months) for coronary vasculopathy (mean (SD)) 15.41 (5.88) 14.15 (5.38) 0.006 14.06 (5.58) 13.98 (5.41) 0.913